265 related articles for article (PubMed ID: 22554547)
1. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.
Galanis E; Wu W; Cloughesy T; Lamborn K; Mann B; Wen PY; Reardon DA; Wick W; Macdonald D; Armstrong TS; Weller M; Vogelbaum M; Colman H; Sargent DJ; van den Bent MJ; Gilbert M; Chang S
Lancet Oncol; 2012 May; 13(5):e196-204. PubMed ID: 22554547
[TBL] [Abstract][Full Text] [Related]
2. Integrated phase II/III clinical trials in oncology: a case study.
Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
[TBL] [Abstract][Full Text] [Related]
3. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
Neven A; Mauer M; Hasan B; Sylvester R; Collette L
J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
5. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
Yoo W; Kim S; Garcia M; Mehta S; Sanai N
BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
[TBL] [Abstract][Full Text] [Related]
7. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
8. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
9. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
10. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
11. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
[TBL] [Abstract][Full Text] [Related]
12. Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?
Parke T; Marchenko O; Anisimov V; Ivanova A; Jennison C; Perevozskaya I; Song G
J Biopharm Stat; 2017; 27(3):457-476. PubMed ID: 28281911
[TBL] [Abstract][Full Text] [Related]
13. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
Huang RY; Wen PY
Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
[TBL] [Abstract][Full Text] [Related]
14. [Randomized Phase II Trial Designs in Oncology].
Yoshimura K
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1561-1566. PubMed ID: 30449838
[TBL] [Abstract][Full Text] [Related]
15. Current issues in oncology drug development, with a focus on Phase II trials.
Sargent DJ; Taylor JM
J Biopharm Stat; 2009; 19(3):556-62. PubMed ID: 19384696
[TBL] [Abstract][Full Text] [Related]
16. Trial design for evaluation of novel targeted therapies.
Farley J; Rose PG
Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
[TBL] [Abstract][Full Text] [Related]
17. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
[TBL] [Abstract][Full Text] [Related]
18. Adaptive seamless designs with interim treatment selection: a case study in oncology.
Carreras M; Gutjahr G; Brannath W
Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Alexander BM; Brown PD; Ahluwalia MS; Aoyama H; Baumert BG; Chang SM; Gaspar LE; Kalkanis SN; Macdonald DR; Mehta MP; Soffietti R; Suh JH; van den Bent MJ; Vogelbaum MA; Wefel JS; Lee EQ; Wen PY;
Lancet Oncol; 2018 Jan; 19(1):e33-e42. PubMed ID: 29304360
[TBL] [Abstract][Full Text] [Related]
20. A review of phase 2-3 clinical trial designs.
Thall PF
Lifetime Data Anal; 2008 Mar; 14(1):37-53. PubMed ID: 17763973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
